Literature DB >> 27466949

Addressing the Conformational Flexibility of Serine Racemase by Combining Targeted Molecular Dynamics, Conformational Sampling and Docking Studies.

Agostino Bruno1, Laura Amori1, Gabriele Costantino2.   

Abstract

Serine racemase (SR) is a PLP-dependent enzyme catalyzing the racemization of L-Ser into D-Ser, which is now recognized as an endogenous co-agonist at the NMDA receptor complex. As indicated by available X-ray structures, SR undergoes significant conformational changes during ligand recognition, and it is conceivable that, in addition to the reported X-ray structures, other intermediate conformational states may have relevance in drug discovery studies. Targeted molecular dynamics (TMD) simulations are an effective tools to follow the conformational transition of a protein under the constrain of reaching a known target states. In this study we use TMD to simulate the transition between the open and closed form of SR in the presence of the endogenous substrate or an orthosteric inhibitor. The trajectories thus obtained are then clustered to collect an ensemble of intermediate conformational states. Docking of a small library of known SR inhibitors or closely related inactive analogs demonstrates that ensemble docking performs better than docking on available crystal structures, thus indicating that inclusion of conformational flexibility into ligand design strategies will be crucial for the development of new classes of SR inhibitors.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Conformational flexibility; Ensemble docking; Serine racemase; Targeted molecular dynamics

Year:  2011        PMID: 27466949     DOI: 10.1002/minf.201000162

Source DB:  PubMed          Journal:  Mol Inform        ISSN: 1868-1743            Impact factor:   3.353


  1 in total

1.  Discovery of novel fragments inhibiting O-acetylserine sulphhydrylase by combining scaffold hopping and ligand-based drug design.

Authors:  Joana Magalhães; Nina Franko; Giannamaria Annunziato; Martin Welch; Stephen K Dolan; Agostino Bruno; Andrea Mozzarelli; Stefano Armao; Aigars Jirgensons; Marco Pieroni; Gabriele Costantino; Barbara Campanini
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.